Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Myeloid 1

Conditions

Melanoma 10Glioma 9Brain Neoplasms 9Neoplasms 3Multiple Myeloma 3Histiocytosis, Langerhans-Cell 3Glioblastoma 3Astrocytoma 3Thyroid Carcinoma, Anaplastic 2Ovarian Neoplasms 2Oligodendroglioma 2Neurofibroma, Plexiform 2Neurocytoma 2Neuroblastoma 2Lung Neoplasms 2Hematologic Neoplasms 2Ganglioneuroma 2Ganglioglioma 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Nonseminomatous germ cell tumor 1

Interventions

trametinib 2dabrafenib 2mirdametinib 1gallium Ga 68 dotatate 1Vincristine 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ga(III)-DOTATOC 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ganglioneuroma × dabrafenib × CNS × Clear all
NCT03975829 2026-06-02

Pediatric Long-Term Follow-up and Rollover Study

Novartis

Phase 4 Recruiting
165 enrolled
CNSMyeloid

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Novartis

Phase 2 Completed
151 enrolled 45 charts 1 FDA
CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡